KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and
efficacy of KD019 in combination with trastuzumab and mFOLFOX-6.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health